Renal impairment is the end outcome of progressive and irreversible silent pathologic processes, which may progress to advanced stages without the patient’s complaints. It is important to prescribe only necessary medication, choose non-nephrotoxic alternatives, and frequently monitor renal function. Some people with renal impairment receive drugs that those with kidney illness should avoid or use with caution. This study demonstrates a relationship between polypharmacy and renal impairment. RAAS (54.3%), metformin (39.3%), and sulfonylurea (20.4%) were the most frequently reported PIP in renal impairment patients. Polypharmacy, stroke, females, and older patients over the age of 80 were the main factors associated with renal impairment. The study included 421 participants (224 female, 197 male), and 66.3% were between the ages of 65 and 75.
Beer’s criteria and literature reviews were used to evaluate renal impairment patients’ medication and to determine the frequency of PIPs. Participants with eGFR less than 60mls/min/1.73 m2 were categorized as renal impaired we then calculated the prevalence of renal impairment and used Poisson multivariable regression model with robust variance to identify associated factors. We used medical records and an interviewer-administered questionnaire for data collection. MethodsĪ cross-sectional study was conducted among PHC clinic attendees aged 65 and older. This study aimed to examine the association between renal impairment and polypharmacy among older Palestinian patients visiting primary healthcare centers and to examine potentially inappropriate medications among older patients.
0 kommentar(er)
